# Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

> **NCT01910441** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 95 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** Glimepiride
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01910441
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 95 (ACTUAL)
- **Why stopped:** The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors (CGMS) which were required to assess the primary end-point.
- **Last updated:** 2015-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01910441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01910441, "Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01910441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*